Regulatory Sourcebook eBook
Read the article:
Selecting the Right CMC Strategy for Biologics
Read the eBook:
BioPharm International’s Regulatory Sourcebook eBook
Smaller biopharma companies must do due diligence with their CMC strategy for BLA filings.
peshkova/Stock.adobe.com
Advancing a novel biologic from bench to patient bedside is a complex and arduous process. The chemistry, manufacturing, and control (CMC) strategy that a biomanufacturer employs is as critical to the filing of an investigational new drug application or biologics license application as conducting clinical trials. Because there is no one-size-fits-all approach to CMC, the strategy is often tailored to each compound’s specific platform and method of delivery. This is especially true for biologics because each one is unique to the indication and often involves a shortened development timeline.
Read this article in BioPharm International’s October 2021 Regulatory Sourcebook eBook.
Read the article:
Selecting the Right CMC Strategy for Biologics
Read the eBook:
BioPharm International’s Regulatory Sourcebook eBook
Khanh Ngo Courtney, PhD, is senior director of Biologics, Avomeen.
BioPharm International
eBook: Regulatory Sourcebook, October 2021
October 2021
Pages: 18–21
When referring to this article, please cite it as K.N. Courtney, “Selecting the Right CMC Strategy for Biologics," BioPharm International Regulatory Sourcebook eBook (October 2021).
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.